- Home
- CISS vs LGVN Comparison
CISS vs LGVN Comparison
Compare CISS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- LGVN
- Stock Information
- Founded
- CISS 2022
- LGVN 2014
- Country
- CISS Greece
- LGVN United States
- Employees
- CISS N/A
- LGVN N/A
- Industry
- CISS Marine Transportation
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CISS Consumer Discretionary
- LGVN Health Care
- Exchange
- CISS Nasdaq
- LGVN Nasdaq
- Market Cap
- CISS 11.9M
- LGVN 25.9M
- IPO Year
- CISS N/A
- LGVN 2021
- Fundamental
- Price
- CISS $1.16
- LGVN $2.09
- Analyst Decision
- CISS
- LGVN Strong Buy
- Analyst Count
- CISS 0
- LGVN 2
- Target Price
- CISS N/A
- LGVN $8.00
- AVG Volume (30 Days)
- CISS 146.9K
- LGVN 393.6K
- Earning Date
- CISS 11-01-2024
- LGVN 11-08-2024
- Dividend Yield
- CISS N/A
- LGVN N/A
- EPS Growth
- CISS N/A
- LGVN N/A
- EPS
- CISS N/A
- LGVN N/A
- Revenue
- CISS $47,503,090.00
- LGVN $1,229,000.00
- Revenue This Year
- CISS N/A
- LGVN $161.78
- Revenue Next Year
- CISS N/A
- LGVN $8.62
- P/E Ratio
- CISS N/A
- LGVN N/A
- Revenue Growth
- CISS 264.29
- LGVN 39.34
- 52 Week Low
- CISS $1.08
- LGVN $0.77
- 52 Week High
- CISS $68.50
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- CISS 49.27
- LGVN 54.70
- Support Level
- CISS $1.08
- LGVN $1.76
- Resistance Level
- CISS $1.25
- LGVN $2.26
- Average True Range (ATR)
- CISS 0.05
- LGVN 0.12
- MACD
- CISS 0.01
- LGVN 0.05
- Stochastic Oscillator
- CISS 47.06
- LGVN 66.00
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.